Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
The Journal of Cell Biology
|
September 6, 2002
Enthoprotin: a novel clathrin-associated protein identified through subcellular proteomics
Sylwia Wasiak, Valerie Legendre-Guillemin, Rosa Puertollano, et al.
Pharmacology Research & Perspectives
|
April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
International Immunopharmacology
|
March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
Li Fu, Dean Gilham, Stephanie C Stotz, et al.
Kidney International Reports
|
June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines
|
June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
Atherosclerosis
|
February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Data in Brief
|
August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
Sylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Atherosclerosis
|
November 27, 2018
Apabetalone downregulates factors and pathways associated with vascular calcification
Dean Gilham, Laura M Tsujikawa, Christopher D Sarsons, et al.
Cardiovascular Therapeutics
|
August 22, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response <i>In Vitro</i>, in Mice and in Patients with Cardiovascular Disease
Sylwia Wasiak, Dean Gilham, Emily Daze, et al.
Molecular and Cellular Biology
|
September 13, 2006
Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasis
Hsiao-Wen Chen, Robert N Rainey, Cynthia E Balatoni, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
The Journal of Cell Biology
|
September 6, 2002
Enthoprotin: a novel clathrin-associated protein identified through subcellular proteomics
Sylwia Wasiak, Valerie Legendre-Guillemin, Rosa Puertollano, et al.
Pharmacology Research & Perspectives
|
April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
International Immunopharmacology
|
March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
Li Fu, Dean Gilham, Stephanie C Stotz, et al.
Kidney International Reports
|
June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines
|
June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
Atherosclerosis
|
February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Data in Brief
|
August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
Sylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Atherosclerosis
|
November 27, 2018
Apabetalone downregulates factors and pathways associated with vascular calcification
Dean Gilham, Laura M Tsujikawa, Christopher D Sarsons, et al.
Cardiovascular Therapeutics
|
August 22, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response <i>In Vitro</i>, in Mice and in Patients with Cardiovascular Disease
Sylwia Wasiak, Dean Gilham, Emily Daze, et al.
Molecular and Cellular Biology
|
September 13, 2006
Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasis
Hsiao-Wen Chen, Robert N Rainey, Cynthia E Balatoni, et al.
Page
of 3